Singapore "Should Lead" In Regional Patent Legislation
Singapore's recently-approved bill (Marketletter November 28) has failed to give the pharmaceutical industry full protection for intellectual property, said senior Glaxo officials visiting the island state, because it does not incorporate safeguards to protect intellectual property rights as laid down in the Trade-Related Intellectual Property Rights (TRIPS) agreement.
All members of the World Trade Organization, which is due to go into effect January 1, 1995 (replacing the General Agreement on Tariffs and Trade; Marketletters passim) are expected to sign the TRIPS agreement.
The Singapore government has said the nation's new patent law will make it easier and cheaper for people to register patents, and Singapore Law Minister Shanmugam Jayakumar told parliament before it passed the bill that some representatives had made suggestions on the bill, taking into account the TRIPS agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze